Skip to main content

Basel Area records impressive startup year 2023

| News

Basel Area records impressive startup year 2023

30.01.2024

In 2023, a total of 30 startups from the Basel Area received fresh capital from investors. Between them, they banked well over 350 million Swiss francs, as the Swiss Venture Capital Report reveals. Noema Pharma, Alentis Therapeutics and Nouscom even placed in the top ten for the largest single investments.

The Basel Area confirmed its reputation as one of the most important startup regions in Switzerland in 2023. According to the Swiss Venture Capital Report 2024, the canton of Basel-Stadt recorded 20 financing rounds last year, which produced an overall investment volume of 248 million Swiss francs. For its part, the canton of Basel-Landschaft recorded eight financing rounds totaling 109 million Swiss francs overall. As a result, both cantons again rank among the ten most important locations for startup financing. The canton of Jura also registered two financing rounds. With growth of 82 percent in terms of the investment volume, Basel-Stadt actually posted the sharpest growth across all cantons.

Three companies from the region also made the list of the top ten largest individual investments. Founded in 2020, the Basel-based Noema Pharma banked 103 million Swiss francs from both existing and new investors, while BaseLaunch portfolio company Alentis Therapeutics, founded in 2019 and based in Allschwil in the canton of Basel-Landschaft, secured investment totaling 94 million Swiss francs. Nouscom, which was founded in Basel back in 2015, benefited from an investment of 65 million Swiss francs.

Five company acquisitions

There was a change of ownership at five companies based in the region last year. Founded in 2015, the Allschwil-based T3 Pharma was acquired by Boehringer Ingelheim, while Vertical Bio in Basel, which was only founded in 2023, is now owned by the French firm Pierre Fabre Laboratories. Herbonis, which is located in Augst in the canton of Basel-Landschaft and was founded in 2001, was taken over by the Belgian company Innovad. Founded in 2008, the Basel-based firm Clinerion was acquired by Citeline in the USA, while the new owner of VectivBio is Ironwood Pharmaceuticals in Boston.

The growth in the Basel Area also reflects the general rise in investments seen across the biotechnology sector. Across Switzerland, growth of 22 percent to 492 million Swiss francs was recorded in this sector.

Conversely, in 2023, the Swiss startup landscape experienced its most significant decline since 2011. At 2,588 million Swiss francs, the volume did still exceed the Covid-19 year of 2020, when the equivalent figure totaled around 2,300 million Swiss francs.

The Swiss Venture Capital Report is published on an annual basis by startupticker.ch in partnership with the Swiss Private Equity & Corporate Finance Association (SECA).

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Do you have a question? We'd like to hear from you.